Efficacy and Safety of Xiezhuoxiaozheng Therapy in Diabetic Kidney Disease: a Clinical Study
1. Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China 2. Beijing University of Chinese Medicine, Beijing 100029, China 3. Department of Nephrology, Beijing Dongcheng First People's Hospital, Beijing 100077, China 4. No. 1 Department of Nephrology, the Affiliated Hospital of Shandong University of TCM, Shandong 250011, China
YANG H W, WANG Y X, WU Q R, et al. Efficacy and safety of Xiezhuoxiaozheng therapy in diabetic kidney disease: a clinical study[J]. Chinese General Practice, 2022, 25 (26) : 3252-3257, 3262.
Hanwen YANG,Yaoxian WANG,Qiaoru WU, et al. Efficacy and Safety of Xiezhuoxiaozheng Therapy in Diabetic Kidney Disease: a Clinical Study[J]. Chinese General Practice, 2022, 25(26): 3252-3257. DOI: 10.12114/j.issn.1007-9572.2022.0193.
杨涵雯,王耀献,吴巧茹等. 泄浊消癥法治疗晚期糖尿病肾脏病的临床研究[J]. 中国全科医学, 2022, 25(26): 3252-3257. DOI: 10.12114/j.issn.1007-9572.2022.0193.
CHON H, SHAWJ E, KARURANGAS,et al. IDF Diabetes Atlas:global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract,2018,138:271-281. DOI:10.1016/j.diabres.2018.02.023.
[2]
ZHANGX X, KONGJ, YUNK. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China:a meta-analysis of observational studies[J]. J Diabetes Res,2020,2020:2315607. DOI:10.1155/2020/2315607.
[3]
ZHANGL X, LONGJ Y, JIANGW S,et al. Trends in chronic kidney disease in China[J]. N Engl J Med,2016,375(9):905-906. DOI:10.1056/NEJMc1602469.
[4]
AMERICAN DIABETES ASSOCIATION. Addendum. 10. cardiovascular disease and risk management:Standards of medical care in diabetes-2020. diabetes care 2020;43(suppl. 1):S111-134[J]. Diabetes Care,2020,43(8):1977-1978. DOI:10.2337/dc20-ad08.
[5]
KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for Anemia in chronic kidney disease[J]. Am J Kidney Dis,2006,47(5 Suppl 3):S11-145. DOI:10.1053/j.ajkd.2006.03.010.
[6]
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int,2013,3(1):1-150.
LEVEYA S, STEVENSL A, SCHMIDC H,et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med,2009,150(9):604-612. DOI:10.7326/0003-4819-150-9-200905050-00006.
TUTTLEK R. Linking metabolism and immunology:diabetic nephropathy is an inflammatory disease[J]. J Am Soc Nephrol,2005,16(6):1537-1538. DOI:10.1681/ASN.2005040393.
[13]
SASSY-PRIGENTC, HEUDESD, MANDETC,et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats[J]. Diabetes,2000,49(3):466-475. DOI:10.2337/diabetes.49.3.466.
[14]
NAVARROJ F, MILENAF J, MORAC,et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy:effect of angiotensin-converting enzyme inhibition and pentoxifylline administration[J]. Am J Nephrol,2006,26(6):562-570. DOI:10.1159/000098004.
[15]
LUIS-RODRIGUEZD, MARTINEZ-CASTELAOA, GORRIZJ L,et al. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy[J]. World J Diabetes,2012,3(1):7-18. DOI:10.4239/wjd.v3.i1.7.